Today March 28 the Swedish market close at 13.00. Danish and Norweigan markets is closed.

Ectin Research is active in biotechnology. The company specializes in research and development of drug candidates. The research is focused on developing drugs that aim to eliminate cancerous tumors in patients, with the greatest focus on the treatment of bladder cancer. In addition, the company intends to develop drugs for the treatment of breast, colorectal and prostate cancer cells.

Quotes for Ectin Research AB

Right Now

+/-
%
0,00%
Latest
High
Low
Volume
0
Turnover (SEK)
0
Market Value (MSEK)
8,2
Time (Latest trade)

Board

CEO

  • Anna Sjöblom-Hallén

Chairperson of the Board

  • Hans-Peter Ostler

Board

  • Christer Edlund
  • Fredrik Andersson
  • Göran Gannedahl
  • Marie-Lois Ivarsson

Largest Owners

Name Capital % Votes % Date
JRS Asset Management AB Client Account 9,84 4,50 2023-12-27
Peter Falk 4,35 19,63 2023-12-27
Ivarsson Medical Research AB 4,33 19,62 2023-12-27
Christer Edlund 4,33 19,62 2023-12-27
Fredrik Andersson 3,95 1,81 2022-04-12
Moll Invest AB 3,28 1,50 2023-12-27
Avanza Pension 3,11 1,42 2023-12-27
GU Ventures 2,70 1,23 2023-12-27
Power Capital Society AB 2,20 1,00 2023-12-27
GOKAP Invest AB 2,06 0,94 2023-12-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-05-21 Delårsrapport 2024-Q1

  • 2024-05-29 Årsstämma 2023

  • 2024-08-27 Delårsrapport 2024-Q2

  • 2024-11-26 Delårsrapport 2024-Q3